MTM

MTM to Begin Operating $50 Million Missouri NEMT Program

Retrieved on: 
Tuesday, November 29, 2022
History, Social services, DMH, Mental health, MTM, Oklahoma Department of Mental Health and Substance Abuse Services, Transport, Missouri Department of Social Services, Health, DSS, MCO, SAINT, Medicine, Health insurance, The Missourians

LAKE SAINT LOUIS, Mo., Nov. 29, 2022 (GLOBE NEWSWIRE) -- MTM is pleased to announce that it will begin operating the statewide Missouri Non-Emergency Medical Transportation (NEMT) program effective Dec. 1, 2022.

Key Points: 
  • LAKE SAINT LOUIS, Mo., Nov. 29, 2022 (GLOBE NEWSWIRE) -- MTM is pleased to announce that it will begin operating the statewide Missouri Non-Emergency Medical Transportation (NEMT) program effective Dec. 1, 2022.
  • MTM has a rich history with the Missouri NEMT program.
  • In 1997, MTM helped the state design its original NEMT brokerage programa truly innovative and pioneering approach to medical transportation at the time.
  • Outside of the statewide NEMT program, MTM has continuously operated NEMT programs for numerous MO HealthNet Managed Care Organizations (MCOs) since NEMT was carved into managed care, providing approximately 132,000 trips annually.

Acxiom Forecasts Top Five Customer Experience Trends for 2023

Retrieved on: 
Monday, November 28, 2022
Metaverse, Software, Professional Services, Online Retail, Data Management, Electronic Commerce, Technology, Artificial Intelligence, Digital Marketing, Data Analytics, Retail, Marketing, Communications, Metaverse, Pressure, Human, Seamless, Automation, AI, Gesture, MTM, IPG, Virtual reality, B2B, The Interpublic Group of Companies, Research, Ageing, Cloud computing, CX, Industrial design, Marketing, Online shopping, Acxiom

Acxiom , the customer intelligence company whose data-driven solutions create business growth by enabling better customer experiences, today unveiled its top customer experience (CX) predictions for 2023.

Key Points: 
  • Acxiom , the customer intelligence company whose data-driven solutions create business growth by enabling better customer experiences, today unveiled its top customer experience (CX) predictions for 2023.
  • "Our report underscores the crucial roles data and customer intelligence play in emerging CX trends and serves as a guide for brands looking to connect with and engage customers in 2023," said David Skinner, Chief Strategy Officer at Acxiom.
  • Regardless of trends, brands must have that essential mix to create customer experiences that resonate with people and drive brand growth.
  • Acxiom is a registered trademark of Acxiom LLC and is part of The Interpublic Group of Companies, Inc. (IPG).

Progressive Care Announces Integration With Salesforce

Retrieved on: 
Wednesday, November 9, 2022
Nature, TPA, Sale, Securities Act of 1933, Data management, MTM, Securities Exchange Act of 1934, OTCQB, Company, Medication therapy management, Drug Quality and Security Act, Third-party administrator, COVID-19, Pharmaceutical industry, Audit

Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of Third-Party Administration (TPA), data management, COVID-19 related diagnostics and vaccinations, 340B contracted pharmacy services, prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.

Key Points: 
  • Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of Third-Party Administration (TPA), data management, COVID-19 related diagnostics and vaccinations, 340B contracted pharmacy services, prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.
  • Forward-Looking Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
  • Such forward-looking statements reflect the Companys expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties.
  • When used herein, the words anticipate, believe, estimate, upcoming, plan, target, intend and expect and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements.

Progressive Care Announces Shareholder Conference Call and Business Update on November 14, 2022

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, MTM, Social media, Zippo Manufacturing Co. v. Zippo Dot Com, Inc., Sale, OTCQB, Company, Medication therapy management, Pharmaceutical industry

MIAMI, FL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company (the Company or Progressive Care), is pleased to announce that the Company has scheduled an investor conference call at 4:30 PM ET on Monday, November 14th, 2022.

Key Points: 
  • MIAMI, FL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company (the Company or Progressive Care), is pleased to announce that the Company has scheduled an investor conference call at 4:30 PM ET on Monday, November 14th, 2022.
  • Those attending the investor conference call will have the opportunity to submit questions concerning the Company to Stuart Smith of SmallCapVoice.Com, Inc. via e-mail: [email protected] by 12:00 PM EST on Friday, November 11th, 2022.
  • For those unable to participate in the live conference call, a replay will be available at https://www.smallcapvoice.com/clients/rxmd/ .
  • For more information about Progressive Care, please visit the companys website.

Longhorn Vaccines & Diagnostics Recognized as BioTech Breakthrough’s “Diagnostics Company of the Year”

Retrieved on: 
Thursday, November 3, 2022
Health, Medical Devices, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Public health, United States Department of Agriculture, RNA, Severe acute respiratory syndrome coronavirus 2, Leadership, DNA, Government, Animal, Pandemic, NA, LLC, Department of Biotechnology, Biopharma LLC, Food, Tuberculosis, Temperature, Biotechnology, RSV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Solution, Monkeypox, Human, Department of Human Services and Health, FDA, HA, Health care, Health, TB, Epitope, Therapy, Vaccine, COVID-19, Collection, Peptide, Infection, Avian influenza, African swine fever virus, Laboratory, Mycobacterium tuberculosis, Program, MTM, Fine chemical, Avian, Longhorn, Genomics, Diagnosis

Longhorn Vaccines & Diagnostics , a One Health and One World company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced it has been named Diagnostics Company of the Year in the second annual BioTech Breakthrough Awards program.

Key Points: 
  • Longhorn Vaccines & Diagnostics , a One Health and One World company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced it has been named Diagnostics Company of the Year in the second annual BioTech Breakthrough Awards program.
  • Our goal is to improve the delivery of molecular diagnostics to serve critical unmet needs in both the developed and developing world, said Longhorn Vaccines and Diagnostics President Jeff Fischer.
  • We offer a heartfelt congratulations on being our choice for Diagnostics Company of the Year!
  • Longhorn Vaccines and Diagnostics LLC is a One Health and One World company based in Maryland that is developing vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics.

Vice President of Government Sales Michael Hammond Joins MTM

Retrieved on: 
Tuesday, November 1, 2022
Medicaid, Baker University, United States Department of Health and Human Services, Human services, Substance Abuse and Mental Health Services Administration, GLOBE, UnitedHealth Group, Industry, Department, District, Veyo, Utah, Region, Health, Transport, College, MTM, Public affairs, SAINT, Mental health service, Solution, RFP, Management, Medicine, Humana

LAKE SAINT LOUIS, Mo., Nov. 01, 2022 (GLOBE NEWSWIRE) -- As part of the organization's ongoing efforts to align its non-emergency medical transportation (NEMT) solutions with the needs of clients, MTM is excited to announce the hiring of Michael Hammond as Vice President of Government Sales.

Key Points: 
  • LAKE SAINT LOUIS, Mo., Nov. 01, 2022 (GLOBE NEWSWIRE) -- As part of the organization's ongoing efforts to align its non-emergency medical transportation (NEMT) solutions with the needs of clients, MTM is excited to announce the hiring of Michael Hammond as Vice President of Government Sales.
  • In 2009, MTM's leadership established MTM Transit, an affiliate that provides direct paratransit and fixed-route transit services.
  • Every year, MTM and MTM Transit collectively remove community barriers for 15.4 million people by providing more than 20.75 million trips in 31 states and the District of Columbia.
  • MTM and MTM Transit are privately held, woman-owned business enterprises.

MedAvail Announces Technology Partnership with Progressive Care, Inc

Retrieved on: 
Wednesday, October 26, 2022
Other Health, Software, Managed Care, General Health, Pharmaceutical, Telemedicine, Virtual Medicine, Technology, Hospitals, Biotechnology, Medical Supplies, Practice Management, Health, Caregiver, Pharmacy, Sale, MTM, NASDAQ, Patient, COO, Partnership, Nasdaq, Technology, National Association of Boards of Pharmacy, LTC, Medicare, Medication therapy management, Progressive, OTCQB, Prescription, Pharmaceutical industry

MedAvail Holdings, Inc. (Nasdaq: MDVL) (MedAvail) a technology-based retail pharmacy company, and Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care) a personalized healthcare services and technology company, are excited to announce a technology agreement to deploy five MedAvail MedCenters in Florida.

Key Points: 
  • MedAvail Holdings, Inc. (Nasdaq: MDVL) (MedAvail) a technology-based retail pharmacy company, and Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care) a personalized healthcare services and technology company, are excited to announce a technology agreement to deploy five MedAvail MedCenters in Florida.
  • MedAvail MedCenters unique medication dispensing technology will allow PharmcoRx, a subsidiary of Progressive Care, to provide pharmacy services in any state where Board of Pharmacy laws allow remote medication dispensing through digitally integrated kiosks.
  • Our partnership with MedAvail will further strengthen our ongoing commitment towards creating a more convenient, quicker, and secure way for patients to receive their medication.
  • One of our top priorities is to expand our technology business segment, and we are pleased to be broadening the reach of our MedCenter technology with this new partnership with Progressive Care.

Longhorn Vaccines and Diagnostics Reports Composite Peptide Vaccines Generate Immune Responses to Both Influenza and Coronavirus

Retrieved on: 
Monday, October 24, 2022
Technology, Health, General Health, Pharmaceutical, Biometrics, Health Technology, Other Science, Other Technology, Infectious Diseases, Science, COVID-19, Immunoglobulin G, Fatigue, DC, Pandemic, Diagnosis, Vaccine, Animal, NA, Severe acute respiratory syndrome coronavirus 2, MTM, Mycobacterium tuberculosis, Health, Epitope, RNA, Temperature, Infection, Mouse, MD, HA, Conservation, T helper cell, DNA, Immunization, Peptide, FDA, Parasitism, Human, TB, Public health, Coronavirus, Longhorn

The data was consistent with Longhorns lead vaccine candidate LHNVD-105, a composite peptide universal influenza vaccine candidate, delivered with the US Armys Liposomal Adjuvant (ALFQ).

Key Points: 
  • The data was consistent with Longhorns lead vaccine candidate LHNVD-105, a composite peptide universal influenza vaccine candidate, delivered with the US Armys Liposomal Adjuvant (ALFQ).
  • Both vaccines generate a robust, durable and balanced immune response.
  • We aim to move our universal influenza vaccine candidate, LHNVD-105, into Phase 1 clinical trials starting in 2023.
  • The combined composite peptide vaccine generated highly enhanced immune responses with only primary immunization, which increased further with a boost (titers up to 100,000).

Quality Gold, A Leading Vertically Integrated Specialty Logistics and Jewelry Distributor, to Become a Publicly Traded Company Via Business Combination with Tastemaker Acquisition Corp.

Retrieved on: 
Friday, October 21, 2022
Registration statement, MTM, Rest, Director, Failure, Business architecture, Communication, Person, GAAP, Stock, NEW, Company, Industry, GLOBE, PPP, Form S-4, Risk, Growth, Annual report, Register, History, Gold, DLA Piper, EBITDA, Prospectus, Name, U.S. Securities and Exchange Commission, Sale, SEC, Madison Avenue, Business, Nasdaq, Jewellery, Acquisition, Form, Proxy, Forward-looking statement, COVID-19, Retail, Video game, Bank, Risk management, Cryptocurrency, Security (finance), Quality, Tastemaker, Stifel

The Company has over 15,000 loyal retail partners, who rely on Quality Golds ability to supply over 165,000 products.

Key Points: 
  • The Company has over 15,000 loyal retail partners, who rely on Quality Golds ability to supply over 165,000 products.
  • Quality Gold enjoys deep relationships with more than 400 strategic suppliers globally and has demonstrated significant efficiencies with ~78% of orders automated.
  • We are excited to take this major step forward in becoming a publicly traded company, said Jason Langhammer.
  • Our decision to go public is intended to supercharge Qualitys Golds growth as the premier jewelry logistics and distribution provider.

Longhorn Vaccines and Diagnostics to Present at Infectious Disease Week 2022

Retrieved on: 
Wednesday, October 19, 2022
Research, General Health, Pharmaceutical, Technology, Infectious Diseases, Health Technology, Science, COVID-19, Biotechnology, Other Technology, Other Science, Health, Pandemic, Diagnosis, Vaccine, Animal, Severe acute respiratory syndrome coronavirus 2, MTM, Mycobacterium tuberculosis, Health, LLC, Infection, RNA, Temperature, 2021 Essex County Council election, DNA, FDA, COVID-19, ID, Human, TB, Public health, Longhorn

Longhorn Vaccines and Diagnostics LLC , a One Health and One World company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced that it will present two abstracts at Infectious Disease (ID) Week, being in Washington, DC, Oct. 19 23, 2022.

Key Points: 
  • Longhorn Vaccines and Diagnostics LLC , a One Health and One World company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced that it will present two abstracts at Infectious Disease (ID) Week, being in Washington, DC, Oct. 19 23, 2022.
  • The abstracts focus on Longhorns work in developing vaccines for a universal influenza vaccine, antimicrobial resistant bacteria, and the companys work in COVID-19.
  • Longhorn Vaccines and Diagnostics LLC is a One Health and One World company based in Maryland that is developing vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics.
  • Since pandemics flow between humans and animals, Longhorn caters to both in order to surveil, diagnose, prevent and treat the next infectious disease.